Search Results
Aug 21, 2025, 08:45 ET Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join - Contact The Gross Law Firm
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Aug 21, 2025, 08:30 ET AI in Molecular Biology: Revolutionizing the Future of Biotech, Upcoming Webinar Hosted by Xtalks
in biotechnology and life sciences. Attendees will learn how accelerated innovation facilitates breakthroughs in synthetic biology, drug discovery, gene therapy and other cutting-edge fields. The featured speaker will share how data-driven decisions empower scientists with predictive analytics and insights
More news about: Xtalks
Aug 21, 2025, 08:00 ET Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction
treatments. About Andelyn Biosciences, Inc. Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn's deep scientific expertise has resulted in
More news about: Andelyn Biosciences
Aug 21, 2025, 07:23 ET Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer
Quantification of cell shedding in urine and the secondary endpoints included Induction of apoptosis, Histopathology scoring, Tumor response to Alpha1H by gene expression analysis, Proteomic analysis of immune markers in urine. Safety was assessed for all patients, who received treatment with investigational
More news about: Hamlet BioPharma AB (publ)
Aug 21, 2025, 07:00 ET Insmed To Present at September Investor Conferences
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Aug 21, 2025, 02:49 ET Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 21, 2025, 02:41 ET Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit:
More news about: Piramal Pharma Solutions
Aug 21, 2025, 01:00 ET GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene, resulting in a deficiency of the IDS enzyme, which is essential for the degradation of glycosaminoglycans (GAGs). This deficiency leads to the progressive
More news about: GC Biopharma
Aug 20, 2025, 17:31 ET HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight
and active gene transcription, HDAC activity leads to histone deacetylation and epigenetic suppression of gene expression. Since HDACs influence many pathways involved in cancer development, HDAC inhibitors (HDACis) show clinical effects through several mechanisms, including changes in gene expression
More news about: DelveInsight Business Research, LLP
Aug 20, 2025, 14:04 ET KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ --
More news about: KROMATID
Aug 20, 2025, 09:18 ET As Chikungunya Emerges Abroad, Florida Stands Guard Against Aedes aegypti and Aedes albopictus Threats
viable offspring—reducing mosquito populations over time.Oxitec's targeted biological control mosquitoes, which carry a self-limiting gene that prevents female offspring from surviving, thereby suppressing the population of Aedes aegypti.Wolbachia technology, which
More news about: Florida Mosquito Control Association
Aug 20, 2025, 09:00 ET San Diego-Area Biotech Startup Achieves Major Breakthrough in the Fight Against Rare Neurodevelopmental Disorder
Rett Syndrome is a devastating, progressive neurodevelopmental disorder caused by mutations in the MECP2 gene. It primarily affects females and is characterized by the loss of previously acquired motor and communication skills, seizures, breathing irregularities,
More news about: Grann Pharmaceuticals Inc.
Aug 20, 2025, 08:49 ET Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
technology platforms based on reprogramming technology, stem cell differentiation technology, SISBAR lineage tracing technology, and high-precision gene editing. By 2025, the company has filed over 20 patent applications, with 4 granted utility model patents and 6 software copyrights. Its self-developed
More news about: UniXell Biotechnology
Aug 20, 2025, 08:32 ET Quintara Biosciences Launches Whole Plasmid Sequencing - Express (WPS-Express) Across Four U.S. Sites
discovery. Quintara Biosciences is a nationwide provider of genomics and molecular biology services, offering sequencing, cloning, and gene synthesis solutions for academic, biotech, and pharmaceutical clients. With labs in Boston, San Francisco,
More news about: Quintara Biosciences
Aug 19, 2025, 20:00 ET XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's
More news about: XtalPi Inc.
Aug 19, 2025, 10:00 ET Texas Children's Provides New Breakthrough Treatment for Patient with Rare Neurological Disorder
energy and happiness." Dr. Curry helped develop the Texas Children's Intracerebral Gene Therapy Program with investigations into intraputamenal gene therapy for AADC deficiency, as well as investigations into gene therapy for Rett syndrome and NGLY-1 deficiency. Dr. Curry is also Director of the Neuroinfusion
More news about: Texas Children's Hospital
Aug 19, 2025, 09:15 ET LabConnect Launches LabConnector™ to Streamline Lab Data Integration
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Aug 19, 2025, 09:15 ET LabConnect Launches LabConnector™ to Streamline Lab Data Integration
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Aug 19, 2025, 09:00 ET Parkinson's Foundation Launches New Program to Accelerate Clinical Trials
meet with and educate PD GENEration participants to help inform them of the PD genetic trials landscape and facilitate their enrollment into gene-targeted clinical trials.
More news about: Parkinson's Foundation
Aug 19, 2025, 08:45 ET Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 19, 2025, 08:00 ET Ultima Genomics and Gene by Gene Partner to Expand Global Access to High-Quality, Low-Cost Sequencing on the UG 100™ Platform
with Gene by Gene to expand access to the UG 100 for researchers and organizations around the world." "Gene by Gene has always been committed to making advanced genetic testing more accessible without compromising quality," said Josh Wittner, President of Gene by Gene.
More news about: Ultima Genomics
Aug 19, 2025, 08:00 ET Steel Dynamics to Acquire Remaining 55% Ownership Interest in New Process Steel
which are located at Steel Dynamics' Butler and Columbus Flat Roll Steel divisions. New Process Steel was purchased in 1952 by Gene Fant, the father of New Process' current Chief Executive Officer, Richard Fant. Richard
More news about: Steel Dynamics, Inc.
Aug 19, 2025, 08:00 ET PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
heart.4 It is the most common hereditary ataxia (abnormal, uncoordinated movements) and is usually caused by a single genetic defect in the frataxin (FXN) gene that leads to reduced production of frataxin, a mitochondrial protein that is important for cellular metabolism and energy production.4,5
More news about: PTC Therapeutics, Inc.
Aug 19, 2025, 06:00 ET Selonterra announces grant of United States patent on original discoveries in Alzheimer's disease
neurodegenerative disorders, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. We harness human genetics, molecular pathway analysis and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics.
More news about: Selonterra, Inc.
Aug 18, 2025, 17:24 ET Quiet Beauty: entenda a tendência estética que respeita resultados minimalistas e mais naturais
lipoatrophy: the US experience. Dermatol Surg 2006;32:1336-4.21. Waibel J Widgerow A et al. A randomized, comparative study describing the gene signatures of poly-llactic acid (PLLA-SCA) and calcium hydroxylapaptite (CAHA) in the treatment of nasolabial folds). Poster presented at the International
More news about: Galderma